Literature DB >> 9823969

Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN.

I C Gray1, L M Stewart, S M Phillips, J A Hamilton, N E Gray, G J Watson, N K Spurr, D Snary.   

Abstract

The chromosomal region 10q23-24 is frequently deleted in a number of tumour types, including prostate adenocarcinoma and glioma. A candidate tumour-suppressor gene at 10q23.3, designated PTENor MMAC1, with putative actin-binding and tyrosine phosphatase domains has recently been described. Mutations in PTEN have been identified in cell lines derived from gliomas, melanomas and prostate tumours and from a number of tumour specimens derived from glial, breast, endometrial and kidney tissue. Germline mutations in PTEN appear to be responsible for Cowden disease. We identified five PTEN mutations in 37 primary prostatic tumours analysed and found that 70% of tumours showed loss or alteration of at least one PTEN allele, supporting the evidence for PTEN involvement in prostate tumour progression. We raised antisera to a peptide from PTEN and showed that reactivity occurs in numerous small cytoplasmic organelles and that the protein is commonly expressed in a variety of cell types. Northern blot analysis revealed multiple RNA species; some arise as a result of alternative polyadenylation sites, but others may be due to alternative splicing.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9823969      PMCID: PMC2063186          DOI: 10.1038/bjc.1998.674

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  11 in total

1.  Germline mutations in PTEN are present in Bannayan-Zonana syndrome.

Authors:  D J Marsh; P L Dahia; Z Zheng; D Liaw; R Parsons; R J Gorlin; C Eng
Journal:  Nat Genet       Date:  1997-08       Impact factor: 38.330

2.  Alterations of PTEN/MMAC1, a candidate tumor suppressor gene, and its homologue, PTH2, in small cell lung cancer cell lines.

Authors:  S K Kim; L K Su; Y Oh; B L Kemp; W K Hong; L Mao
Journal:  Oncogene       Date:  1998-01-08       Impact factor: 9.867

3.  TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta.

Authors:  D M Li; H Sun
Journal:  Cancer Res       Date:  1997-06-01       Impact factor: 12.701

4.  Subcellular separation and molecular nature of human histocompatibility antigens (HL-A).

Authors:  D Snary; P Goodfellow; M J Hayman; W F Bodmer; M J Crumpton
Journal:  Nature       Date:  1974-02-15       Impact factor: 49.962

5.  Frequent inactivation of PTEN/MMAC1 in primary prostate cancer.

Authors:  P Cairns; K Okami; S Halachmi; N Halachmi; M Esteller; J G Herman; J Jen; W B Isaacs; G S Bova; D Sidransky
Journal:  Cancer Res       Date:  1997-11-15       Impact factor: 12.701

6.  Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues.

Authors:  H Suzuki; D Freije; D R Nusskern; K Okami; P Cairns; D Sidransky; W B Isaacs; G S Bova
Journal:  Cancer Res       Date:  1998-01-15       Impact factor: 12.701

7.  Mutation analysis of the putative tumor suppressor gene PTEN/MMAC1 in primary breast carcinomas.

Authors:  E Rhei; L Kang; F Bogomolniy; M G Federici; P I Borgen; J Boyd
Journal:  Cancer Res       Date:  1997-09-01       Impact factor: 12.701

8.  MMAC1/PTEN mutations in primary tumor specimens and tumor cell lines.

Authors:  D H Teng; R Hu; H Lin; T Davis; D Iliev; C Frye; B Swedlund; K L Hansen; V L Vinson; K L Gumpper; L Ellis; A El-Naggar; M Frazier; S Jasser; L A Langford; J Lee; G B Mills; M A Pershouse; R E Pollack; C Tornos; P Troncoso; W K Yung; G Fujii; A Berson; P A Steck
Journal:  Cancer Res       Date:  1997-12-01       Impact factor: 12.701

9.  Somatic mutations of PTEN in glioblastoma multiforme.

Authors:  S I Wang; J Puc; J Li; J N Bruce; P Cairns; D Sidransky; R Parsons
Journal:  Cancer Res       Date:  1997-10-01       Impact factor: 12.701

10.  PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer.

Authors:  J Li; C Yen; D Liaw; K Podsypanina; S Bose; S I Wang; J Puc; C Miliaresis; L Rodgers; R McCombie; S H Bigner; B C Giovanella; M Ittmann; B Tycko; H Hibshoosh; M H Wigler; R Parsons
Journal:  Science       Date:  1997-03-28       Impact factor: 47.728

View more
  56 in total

1.  Pten, a protean tumor suppressor.

Authors:  G L Mutter
Journal:  Am J Pathol       Date:  2001-06       Impact factor: 4.307

Review 2.  Targeting the PI3-kinase/Akt/mTOR signaling pathway.

Authors:  Burhan Hassan; Argun Akcakanat; Ashley M Holder; Funda Meric-Bernstam
Journal:  Surg Oncol Clin N Am       Date:  2013-08-06       Impact factor: 3.495

3.  ERG overexpression and PTEN status predict capsular penetration in prostate carcinoma.

Authors:  Raymond B Nagle; Amit M Algotar; Connie C Cortez; Katherine Smith; Carol Jones; Ubaradka G Sathyanarayana; Steven Yun; Janice Riley; Dea Nagy; Ryan Dittamore; Bruce Dalkin; Laura Brosh; Gary Pestano
Journal:  Prostate       Date:  2013-05-07       Impact factor: 4.104

4.  Novel combination of docetaxel and thymoquinone induces synergistic cytotoxicity and apoptosis in DU-145 human prostate cancer cells by modulating PI3K-AKT pathway.

Authors:  A Dirican; H Atmaca; E Bozkurt; C Erten; B Karaca; R Uslu
Journal:  Clin Transl Oncol       Date:  2014-07-25       Impact factor: 3.405

Review 5.  Management of metastatic castration-resistant prostate cancer: recent advances.

Authors:  Deborah Mukherji; Andrew Eichholz; Johann S De Bono
Journal:  Drugs       Date:  2012-05-28       Impact factor: 9.546

6.  Differential requirement of mTOR in postmitotic tissues and tumorigenesis.

Authors:  Caterina Nardella; Arkaitz Carracedo; Andrea Alimonti; Robin M Hobbs; John G Clohessy; Zhenbang Chen; Ainara Egia; Alessandro Fornari; Michelangelo Fiorentino; Massimo Loda; Sara C Kozma; George Thomas; Carlos Cordon-Cardo; Pier Paolo Pandolfi
Journal:  Sci Signal       Date:  2009-01-27       Impact factor: 8.192

7.  Activation of Notch1 synergizes with multiple pathways in promoting castration-resistant prostate cancer.

Authors:  Tanya Stoyanova; Mireille Riedinger; Shu Lin; Claire M Faltermeier; Bryan A Smith; Kelvin X Zhang; Catherine C Going; Andrew S Goldstein; John K Lee; Justin M Drake; Meghan A Rice; En-Chi Hsu; Behdokht Nowroozizadeh; Brandon Castor; Sandra Y Orellana; Steven M Blum; Donghui Cheng; Kenneth J Pienta; Robert E Reiter; Sharon J Pitteri; Jiaoti Huang; Owen N Witte
Journal:  Proc Natl Acad Sci U S A       Date:  2016-09-30       Impact factor: 11.205

8.  Regulators of gene expression as biomarkers for prostate cancer.

Authors:  Stacey S Willard; Shahriar Koochekpour
Journal:  Am J Cancer Res       Date:  2012-11-20       Impact factor: 6.166

9.  PTEN protein expression in malignant pleural mesothelioma.

Authors:  Vijay Agarwal; Anne Campbell; Kate L Beaumont; Lynn Cawkwell; Michael J Lind
Journal:  Tumour Biol       Date:  2012-12-15

10.  Identification of nucleolus-localized PTEN and its function in regulating ribosome biogenesis.

Authors:  Pingdong Li; Danni Wang; Haiyang Li; Zhenkun Yu; Xiaohong Chen; Jugao Fang
Journal:  Mol Biol Rep       Date:  2014-06-27       Impact factor: 2.316

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.